Grace Therapeutics, IncNASDAQ:GRCE
- LAST PRICE3.1350
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.8100/ 5
- Ask / Lots3.4500/ 1
- Open / Previous Close--- / 3.1350
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GRCE |
|---|---|---|
| 09:32 ET | 342 | 3.1 |
| 09:37 ET | 116 | 3.256 |
| 09:39 ET | 400 | 3.1 |
| 10:02 ET | 1667 | 3.1394 |
| 10:13 ET | 974 | 3.0145 |
| 10:27 ET | 429 | 3.14 |
| 10:45 ET | 152 | 3.04605 |
| 10:47 ET | 233 | 3.075 |
| 11:21 ET | 1019 | 3.08 |
| 11:48 ET | 367 | 3.065 |
| 11:59 ET | 200 | 3.06 |
| 12:44 ET | 1895 | 3.05 |
| 12:50 ET | 2000 | 3.05 |
| 02:57 ET | 401 | 3.139 |
| 03:33 ET | 300 | 3.135 |
Oct 30, 2024
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024, from 8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 28, 2024
*DJ News On Acasti Pharma Inc. (ACST) Now Under GRCE, from 5:08PM ET on Monday Oct 28, 2024 by Dow Jones
5:08PM ET on Monday Oct 28, 2024 by Dow Jones
Oct 25, 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc., from 8:00AM ET on Friday Oct 25, 2024 by Dow Jones
8:00AM ET on Friday Oct 25, 2024 by Dow Jones*DJ Acasti Announces Corporate Name Change to Grace Therapeutics, from 8:00AM ET on Friday Oct 25, 2024 by Dow Jones
8:00AM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Grace Therapeutics, Inc | 31.8M | -2.6x | --- |
ALT5 Sigma Corp | 31.8M | -0.7x | --- |
AN2 Therapeutics Inc | 32.2M | -0.5x | --- |
LianBio | 31.3M | -0.4x | --- |
Impact Biomedical Inc | 31.3M | -7.4x | --- |
Ocean Biomedical Inc | 31.2M | -0.3x | --- |
Company Information
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.
Contact Information
- Headquarters
- 103 Carnegie Center, Suite 300PRINCETON, NJ, United States 08540
- Phone
- 609-322-1602
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Vimal Kavuru
- Chief Executive Officer, Director
- Prashant Kohli
- Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
- Robert Delaversano
- Vice President - Clinical Operations
- Carrie D'Andrea
- Vice President - Program Management
- Amresh Kumar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.50 |
EPS | $-1.22 |
Book Value | $6.57 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
